Transporters in proximal renal tubules contribute to the disposition of numerous drugs.
Furthermore, the molecular mechanisms of tubular secretion have been progressively …

With the discovery of P-glycoprotein (P-gp), it became evident that ABC-transporters play a
vital role in bioavailability and toxicity of drugs. They prevent intracellular accumulation of …

The human intestinal mucosa is a critical site for absorption, distribution, metabolism, and
excretion (ADME)/Tox studies in drug development and is difficult to recapitulate in vitro …

Physiologically‐based pharmacokinetic (PBPK) modeling has been extensively used to
quantitatively translate in vitro data and evaluate temporal effects from drug–drug …

In vitro evaluation of P-glycoprotein (P-gp) inhibitory potential is now a regulatory issue
during drug development, in order to predict clinical inhibition of P-gp and subsequent drug …

In recent years, an increasing number of clinical drug–drug interactions (DDIs) have been
attributed to inhibition of intestinal organic anion-transporting polypeptides (OATPs); …

The International Transporter Consortium (ITC) organized a second workshop in March
2012 to expand on the themes developed during the inaugural ITC workshop held in 2008 …

The role of P‐glycoprotein (P‐gp) and breast cancer resistance protein (BCRP) in drug–drug
interactions (DDIs) and limiting drug absorption as well as restricting the brain penetration of …

Organic cation transporter (OCT) 2 mediates the entry step for organic cation secretion by
renal proximal tubule cells and is a site of unwanted drug-drug interactions (DDIs). But …

The intestinal efflux transporter breast cancer resistance protein (BCRP) restricts the
absorption of rosuvastatin. Of the transporters important to rosuvastatin disposition …